Platelet Count（PC）/Spleen Diameter(SD) Ratio to Predict the Variceal Haemorrhage in HBV Cirrhotic Patients in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02546414

Enrollment

150

Registered

2015-09-10

Start date

2013-01-31

Completion date

2015-08-31

Last updated

2015-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child-Pugh Classification, Platelet Count/Spleen Diameter Ratio

Keywords

Platelet count/spleen diameter ratio, China

Brief summary

To validate the PC/SD ratio to be used to predict the variceal haemorrhage in Chinese patients with hepatitis B virus (HBV)-associated hepatic cirrhosis.

Detailed description

Esophageal variceal bleeding remains the leading cause of acute mortality in patients with cirrhosis. Using noninvasive parameters for high-risk variceal haemorrhage may reduce the need for endoscopies. The ratio of platelet count/diameter of the spleen (PC/SD ratio) is the principal noninvasive predictor of esophageal varices. This was an analytical cross-sectional study to validate the diagnostic test for HBV hepatic cirrhosis and was performed between January 2013 and August 2015. This study is to validate the PC/SD ratio to identification of those patients with high bleeding risk and selection for prophylactic treatment.

Interventions

OTHERPlatelet count/spleen diameter ratio

Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients with a diagnosis of HBV hepatic cirrhosis

Exclusion criteria

* Patients with hepatocellular carcinoma, * use of medications for the primary prophylaxis of variceal bleeding, * history of esophageal variceal bleeding, * alcohol consumption within the admission and a history of ligation, * sclerotherapy, and/or * portal hypertension surgery

Design outcomes

Primary

Measure	Time frame	Description
Platelet count/spleen diameter ratio	up to 2.5 years	This was an analytical cross-sectional study to validate the diagnostic test for HBV hepatic cirrhosis and was performed between January 2013 and August 2015

Secondary

Measure	Time frame	Description
Child-Pugh score.	up to 2.5 years	This was an analytical cross-sectional study to validate the diagnostic test for HBV hepatic cirrhosis and was performed between January 2013 and August 2015

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026